[{"id":"b551a935-be79-4c85-a549-f8121bd6223c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00716976","created_at":"2023-08-23T13:08:30.048Z","updated_at":"2024-07-02T16:35:29.811Z","phase":"Phase 3","brief_title":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","source_id_and_acronym":"NCT00716976","lead_sponsor":"Children's Oncology Group","biomarkers":" COMT","pipe":" | ","alterations":" TPMT mutation","tags":["COMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TPMT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 06/23/2008","start_date":" 06/23/2008","primary_txt":" Primary completion: 04/09/2015","primary_completion_date":" 04/09/2015","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2023-11-09"},{"id":"13a5e519-7fde-415b-8dc6-2319ff68e863","acronym":"","url":"https://clinicaltrials.gov/study/NCT02039505","created_at":"2021-03-18T07:53:16.055Z","updated_at":"2024-07-02T16:37:00.195Z","phase":"Phase 3","brief_title":"Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis","source_id_and_acronym":"NCT02039505","lead_sponsor":"Takeda","biomarkers":" TPMT","pipe":" | ","alterations":" TPMT mutation","tags":["TPMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TPMT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Entyvio (vedolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 292","initiation":"Initiation: 02/04/2014","start_date":" 02/04/2014","primary_txt":" Primary completion: 02/27/2018","primary_completion_date":" 02/27/2018","study_txt":" Completion: 06/28/2018","study_completion_date":" 06/28/2018","last_update_posted":"2019-04-25"}]